FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3111195825> ?p ?o ?g. }

• W3111195825 endingPage "1574" @default.
• W3111195825 startingPage "1564" @default.
• W3111195825 abstract "Warfarin remains the oral anticoagulant of choice in sub‐Saharan Africa. However, dosing is challenging due to a highly variable clinical response for a given dose. This study aimed to develop and validate a clinical warfarin dose‐initiation model in sub‐Saharan Black‐African patients. For the development cohort, we used data from 364 patients who were recruited from 8 outpatient clinics and hospital departments in Uganda and South Africa (June 2018–July 2019). Validation was undertaken using the International Warfarin Pharmacogenetics Consortium (IWPC) dataset (690 black patients). Four predictors (age, weight, target International Normalized Ratio range, and HIV status) were included in the final model, which achieved mean absolute errors (MAEs; mean of absolute differences between true dose and dose predicted by the model) of 11.6 (95% confidence interval (CI) 10.4–12.8) and 12.5 (95% CI 11.6–13.4) mg/week in the development and validation cohorts, respectively. Two other clinical models, IWPC and Gage, respectively, obtained MAEs of 12.5 (95% CI 11.3–13.7) and 12.7 (95% CI 11.5–13.8) mg/week in the development cohort, and 12.1 (95% CI 11.2–13.0) and 12.2 (95% CI 11.4–13.1) mg/week in the validation cohort. Compared with fixed dose‐initiation, our model decreased the percentage of patients at high risk of suboptimal anticoagulation by 7.5% (1.5–13.7%) and 11.9% (7.1–16.8%) in the development and validation cohorts, respectively. The clinical utility of this model will be tested in a prospective study. Study Highlights WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? ☑ Warfarin dosing remains challenging due to a highly variable clinical response for a given dose. WHAT QUESTION DID THIS STUDY ADDRESS? ☑ Can a clinical dose‐initiation model be developed and validated for sub‐Saharan Black‐African patients? WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? ☑ We have developed the first warfarin dose‐initiation clinical model for Black‐African patients in Uganda and South Africa. HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE? ☑ We will be implementing and validating this model in a prospective cohort to inform future large‐scale implementation. More optimized dosing should improve the quality of warfarin anticoagulation in these two developing countries." @default.
• W3111195825 created "2020-12-21" @default.
• W3111195825 creator A5006847944 @default.
• W3111195825 creator A5007109117 @default.
• W3111195825 creator A5036802370 @default.
• W3111195825 creator A5039906428 @default.
• W3111195825 creator A5047661674 @default.
• W3111195825 creator A5059187210 @default.
• W3111195825 creator A5061991607 @default.
• W3111195825 creator A5064591758 @default.
• W3111195825 creator A5068703662 @default.
• W3111195825 creator A5081855852 @default.
• W3111195825 creator A5084854754 @default.
• W3111195825 creator A5086632008 @default.
• W3111195825 creator A5090756265 @default.
• W3111195825 date "2020-12-28" @default.
• W3111195825 modified "2023-10-03" @default.
• W3111195825 title "Developing and Validating a Clinical Warfarin Dose‐Initiation Model for Black‐African Patients in South Africa and Uganda" @default.
• W3111195825 cites W1515782956 @default.
• W3111195825 cites W1920947146 @default.
• W3111195825 cites W1981483370 @default.
• W3111195825 cites W1994682257 @default.
• W3111195825 cites W2003143162 @default.
• W3111195825 cites W2034561962 @default.
• W3111195825 cites W2087046046 @default.
• W3111195825 cites W2090697855 @default.
• W3111195825 cites W2099046070 @default.
• W3111195825 cites W2111796098 @default.
• W3111195825 cites W2115098571 @default.
• W3111195825 cites W2118502261 @default.
• W3111195825 cites W2131886876 @default.
• W3111195825 cites W2134843796 @default.
• W3111195825 cites W2137888687 @default.
• W3111195825 cites W2141813332 @default.
• W3111195825 cites W2146235614 @default.
• W3111195825 cites W2151936813 @default.
• W3111195825 cites W2157839219 @default.
• W3111195825 cites W2171370925 @default.
• W3111195825 cites W2172085497 @default.
• W3111195825 cites W2229752814 @default.
• W3111195825 cites W2294467502 @default.
• W3111195825 cites W2363815377 @default.
• W3111195825 cites W2410566890 @default.
• W3111195825 cites W2412302878 @default.
• W3111195825 cites W2786842288 @default.
• W3111195825 cites W2803436921 @default.
• W3111195825 cites W2884223170 @default.
• W3111195825 cites W2895782022 @default.
• W3111195825 cites W2907638671 @default.
• W3111195825 cites W2946597534 @default.
• W3111195825 cites W2987474774 @default.
• W3111195825 cites W2995598335 @default.
• W3111195825 cites W3003893050 @default.
• W3111195825 cites W4292528167 @default.
• W3111195825 doi "https://doi.org/10.1002/cpt.2128" @default.
• W3111195825 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33280090" @default.
• W3111195825 hasPublicationYear "2020" @default.
• W3111195825 type Work @default.
• W3111195825 sameAs 3111195825 @default.
• W3111195825 citedByCount "8" @default.
• W3111195825 countsByYear W31111958252021 @default.
• W3111195825 countsByYear W31111958252022 @default.
• W3111195825 countsByYear W31111958252023 @default.
• W3111195825 crossrefType "journal-article" @default.
• W3111195825 hasAuthorship W3111195825A5006847944 @default.
• W3111195825 hasAuthorship W3111195825A5007109117 @default.
• W3111195825 hasAuthorship W3111195825A5036802370 @default.
• W3111195825 hasAuthorship W3111195825A5039906428 @default.
• W3111195825 hasAuthorship W3111195825A5047661674 @default.
• W3111195825 hasAuthorship W3111195825A5059187210 @default.
• W3111195825 hasAuthorship W3111195825A5061991607 @default.
• W3111195825 hasAuthorship W3111195825A5064591758 @default.
• W3111195825 hasAuthorship W3111195825A5068703662 @default.
• W3111195825 hasAuthorship W3111195825A5081855852 @default.
• W3111195825 hasAuthorship W3111195825A5084854754 @default.
• W3111195825 hasAuthorship W3111195825A5086632008 @default.
• W3111195825 hasAuthorship W3111195825A5090756265 @default.
• W3111195825 hasConcept C126322002 @default.
• W3111195825 hasConcept C187212893 @default.
• W3111195825 hasConcept C201903717 @default.
• W3111195825 hasConcept C2776301958 @default.
• W3111195825 hasConcept C2777288759 @default.
• W3111195825 hasConcept C2779161974 @default.
• W3111195825 hasConcept C2992750412 @default.
• W3111195825 hasConcept C44249647 @default.
• W3111195825 hasConcept C71924100 @default.
• W3111195825 hasConcept C72563966 @default.
• W3111195825 hasConceptScore W3111195825C126322002 @default.
• W3111195825 hasConceptScore W3111195825C187212893 @default.
• W3111195825 hasConceptScore W3111195825C201903717 @default.
• W3111195825 hasConceptScore W3111195825C2776301958 @default.
• W3111195825 hasConceptScore W3111195825C2777288759 @default.
• W3111195825 hasConceptScore W3111195825C2779161974 @default.
• W3111195825 hasConceptScore W3111195825C2992750412 @default.
• W3111195825 hasConceptScore W3111195825C44249647 @default.
• W3111195825 hasConceptScore W3111195825C71924100 @default.
• W3111195825 hasConceptScore W3111195825C72563966 @default.
• W3111195825 hasIssue "6" @default.

• next